With Setara, the team behind Actio opens its second act
Source: BioPharma Dive - Latest News
The fledgling startup has $90 million to develop a pipeline of drugs, led by a Charcot-Marie-Tooth disease medicine, that Actio was working on when Jazz Pharmaeuticals bought its lead epilepsy program.